Important note: Information in this article was accurate in August 2004. The state of the art August have changed since the publication date.
Antiretroviral Therapy: Addition of tenofovir decreases AUC for atazanavir in HIV-treated patients
AIDSWEEKLY Plus; Monday, August 16, 2004 Staff Medical Writers
NewsRx -- The addition of tenofovir decreases the area-under-the-curve for atazanavir in HIV-treated patients.According to recent research from France, "The aim of the present study was to assess the pharmacokinetic behavior of atazanavir-ritonavir when it is coadministered with tenofovir disoproxil fumarate (DF) in human immunodeficiency virus (HIV)-infected patients."Eleven patients enrolled in Agence Nationale de Recherche sur le SIDA (National Agency for AIDS Research, Paris, France) trial 107 were included in this pharmacokinetic study. They received atazanavir at 300 mg and ritonavir at 100 mg once a day (QD) from day 1 to the end of study.""For the first 2 weeks," wrote A.M. Taburet and coworkers, "their nucleoside analog reverse transcriptase inhibitor (NRTI) treatments remained unchanged. Tenofovir DF was administered QD from day 15 to the end of the study. Ongoing NRTIs were selected according to the reverse transcriptase genotype of the HIV isolates from each patient.""The values of the pharmacokinetic parameters for atazanavir and ritonavir were measured before (day 14 [week 2]) and after (day 42 [week 6]) initiation of tenofovir DF and are reported for the 10 patients who completed the study."There was a significant decrease in the area under the concentration-time curve from 0 to 24 hours (AUC0-24) for atazanavir with the addition of tenofovir DF (AUC0-24 ratio, 0.75; 90% confidence interval, 0.58 to 0.97; p=.05)," the authors reported."There was a trend for a decrease in the minimum concentrations of atazanavir and ritonavir in plasma when they were combined with tenofovir," said investigators, "but none of the differences reached statistical significance. The median decreases in the HIV RNA loads at week 2 and week 6 were 0.1 and 0.2 log copies/ml, respectively.""In summary, our data are consistent with the existence of a significant interaction between atazanavir and tenofovir DF," Taburet concluded.Taburet and colleagues published their study in Antimicrobial Agents and Chemotherapy (Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004 Jun;48(6):2091-6.For additional information, contact A.M. Taburet, Hop Bicetre, Assistance Publ Hop Paris, Department of Clinical Pharmacy, 78 Rue General Leclerc, F-94270 Le Kremlin Bicetre, France.Publisher contact information for the journal Antimicrobial Agents and Chemotherapy is: American Society of Microbiology, 1752 N St. NW, Washington, DC 20036-2904 USA.The information in this article comes under the major subject areas of AIDS/HIV, Immunology, Genomics and Genetics, and Antiretroviral Therapy.This article was prepared by AIDS Weekly editors from staff and other reports.Reference
Taburet AM, Piketty C, Chazallon C, et al., "Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.", Antimicrob Agents Chemother. 2004 Jun;48(6):2091-6.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in August 2004. The state of the art August have changed since the publication date.
